These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 12542737)

  • 1. Detection of platelet-reactive antibodies in patients who are refractory to platelet transfusions, and the selection of compatible donors.
    Vox Sang; 2003 Jan; 84(1):73-88. PubMed ID: 12542737
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevalence of platelet-specific antibodies and efficacy of crossmatch-compatible platelet transfusions in refractory patients.
    Jia Y; Li W; Liu N; Zhang K; Gong Z; Li D; Wang L; Wang D; Jing Y; Wang J; Shan X
    Transfus Med; 2014 Dec; 24(6):406-10. PubMed ID: 25327352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness.
    Wang J; Xia W; Deng J; Xu X; Shao Y; Ding H; Chen Y; Liu J; Chen D; Ye X; Santoso S
    Transfus Med; 2018 Feb; 28(1):40-46. PubMed ID: 28516675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness].
    Basire A; Picard C
    Transfus Clin Biol; 2014 Nov; 21(4-5):193-206. PubMed ID: 25277423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological aspects of platelet transfusions.
    Murphy MF; Waters AH
    Br J Haematol; 1985 Jul; 60(3):409-14. PubMed ID: 4015986
    [No Abstract]   [Full Text] [Related]  

  • 6. Identifying human leukocyte antigen (HLA)-compatible platelets using the Matchmaker programme in alloimmunised platelet-refractory patients.
    Kreuter JD
    Transfus Med; 2020 Feb; 30(1):5-6. PubMed ID: 32187786
    [No Abstract]   [Full Text] [Related]  

  • 7. The challenge of platelet alloimmunization: management and prevention.
    Kickler TS
    Transfus Med Rev; 1990 Oct; 4(4 Suppl 1):8-18. PubMed ID: 2134640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis and treatment of immunological platelet refractoriness by histocompatibility.
    Fagundes IS; Franz JM; Jobim MS; Arend A; Merzoni J; Cardone JM; Gil B; Sekine L; Jobim LF
    Hum Immunol; 2020 May; 81(5):197-201. PubMed ID: 32067841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions.
    Trial to Reduce Alloimmunization to Platelets Study Group
    N Engl J Med; 1997 Dec; 337(26):1861-9. PubMed ID: 9417523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of HLA and platelet-reactive antibodies in alloimmunized patients refractory to platelet therapy.
    Brubaker DB; Romine M
    Am J Hematol; 1987 Dec; 26(4):341-52. PubMed ID: 3687931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of single donor platelets.
    Kirkley SA; Blumberg N
    Blood Rev; 1994 Sep; 8(3):142-7. PubMed ID: 7819816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of HLA- and HPA--matched platelets in alloimmunized patients.
    Kekomäki R
    Vox Sang; 1998; 74 Suppl 2():359-63. PubMed ID: 9704468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serious adverse events after HPA-incompatible platelet transfusions in an alloimmunized patient with leukaemia.
    Sirén MK; Koponen A; Kekomäki R
    Transfus Med; 1998 Sep; 8(3):221-4. PubMed ID: 9800295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of platelet transfusion refractoriness: the use of platelet transfusions matched for both human leucocyte antigens (HLA) and human platelet alloantigens (HPA) in alloimmunized patients with leukaemia.
    Kekomäki S; Volin L; Koistinen P; Koivunen E; Koskimies S; Ruutu T; Timonen T; Kekomäki R
    Eur J Haematol; 1998 Feb; 60(2):112-8. PubMed ID: 9508352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of in vitro assays in selection of compatible platelet donors.
    Tosato G; Appelbaum FR; Trapani RJ; Dowling R; Deisseroth AB
    Transfusion; 1980; 20(1):47-54. PubMed ID: 7355471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful transfusion of platelets "mismatched" for HLA antigens to alloimmunized thrombocytopenic patients.
    Duquesnoy RJ; Filip DJ; Rodey GE; Rimm AA; Aster RH
    Am J Hematol; 1977; 2(3):219-26. PubMed ID: 596366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How do I … manage the platelet transfusion-refractory patient?
    Juskewitch JE; Norgan AP; De Goey SR; Duellman PM; Wakefield LL; Gandhi MJ; Stubbs JR; Kreuter JD
    Transfusion; 2017 Dec; 57(12):2828-2835. PubMed ID: 28960321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The need of a registry of HLA-phenotyped platelet donors].
    Castro Izaguirre E; Muncunill Ribas J
    Med Clin (Barc); 1995 Nov; 105(18):696-9. PubMed ID: 8538251
    [No Abstract]   [Full Text] [Related]  

  • 19. Management of patients with hematologic malignancies and aplastic anemia who are refractory to platelet transfusions.
    Sandler SG
    Haematologia (Budap); 1998; 29(1):1-11. PubMed ID: 9704252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet transfusion therapy in an alloimmunized patient. The value of crossmatch procedures for donor selection.
    Hecht T; Wolf JL; Mraz L; Scott EP; Patz LD
    JAMA; 1982 Nov; 248(18):2301-3. PubMed ID: 6752444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.